AXLRx is a custom-built commercial consulting engine. It delivers evidence-led answers to the commercial questions that move your decision: competitive, patient and payer intelligence, scoped to your asset, delivered in 72 hours. A syndicated report describes the market. An AXLRx report frames the decision your launch and access teams have to make — intelligence you can put in front of a payer.
It is a service, not a subscription. There is no platform to operate, no seat licence and no dashboard to learn. You bring the question in front of you, and we return a PDF report, an Excel model and a PowerPoint readout. Every figure is verified against a live source. If it cannot be sourced, it does not ship.
Three disciplines, one standard: verify or drop.
Live connectors to the primary record: regulatory, clinical, epidemiological, financial and payer sources. No secondary summaries.
Every claim is cited to a live PMID, trial ID or URL at the point of writing, numerically cross-checked, then re-checked in an independent audit pass. Model memory is never a source.
A decision-structured PDF, an editable Excel model and a PowerPoint readout. Every report includes an analyst review and a 30-minute call.
Built by pharma strategy veterans — not generalist AI engineers.
Pharma strategy and market intelligence across GCC, South Asia and Europe. Specialisation in rare disease, specialty and market access.
Former strategy-consulting and in-house commercial analysts who author and review every report against the verify-or-drop standard.
Clinical and ex-payer advisors who pressure-test the commercial read for each therapy area before delivery.
Scope confirmed in 24 hours. Delivered in 72.